Naringenin ameliorates iron overload-associated osteoporosis via Tfeb/p62/Nrf2-mediated antioxidation

Abstract

Postmenopausal women, elderly individuals, and transfusion-dependent patients are prone to bone marrow iron overload, which is closely associated with iron overload-associated osteoporosis (IOOP). Currently, the treatment of IOOP mainly focuses on promoting iron efflux and alleviating iron-induced damage, but the intervention value of natural active ingredients remains unclear. Naringenin (NAR), as a natural flavonoid, can regulate bone metabolism, yet its role and mechanism in IOOP have not been elucidated. In this study, an in vitro model was established by inducing MC3T3-E1 cells with ferric ammonium citrate (FAC), and an in vivo IOOP model was constructed by inducing mice with iron dextran to investigate the effects and mechanisms of NAR. The results showed that NAR improved the alkaline phosphatase (ALP) activity and mineralization capacity of FAC-induced iron-overloaded cells, upregulated the expression of collagen I (Col1a1) and runt-related transcription factor 2 (Runx2), reduced the accumulation of reactive oxygen species (ROS) and lipid peroxide (LPO), attenuated mitochondrial membrane potential (MMP) impairment, and inhibited apoptosis. In in vivo experiments, NAR restored the density and quantity of trabecular bone in iron-overloaded mice. Mechanistically, RNA sequencing indicated that the effect of NAR was associated with transcription factor EB (Tfeb)-dependent transcription: NAR promoted Tfeb nuclear translocation and upregulated p62 transcription under iron overload conditions. Co-immunoprecipitation (Co-IP) demonstrated that NAR enhanced the binding of p62 to kelch-like ECH associated protein 1 (Keap1), while increasing Nrf2 phosphorylation and upregulating its key effector proteins HO-1 and NQO1. Functional validation showed that the Nrf2 antagonist ML385 or siRNA could block the effects of NAR without affecting Tfeb expression, whereas the Tfeb inhibitor eltrombopag simultaneously inhibited Nrf2 expression and NAR-induced effects. In conclusion, NAR alleviates iron overload-induced oxidative damage and osteogenic disorders via the Tfeb/p62/Nrf2 pathway, suggesting that it may serve as a potential therapeutic agent for IOOP.

Keywords

Iron overload / Naringenin / Osteoporosis / Tfeb/p62/Nrf2 Pathway / Bone formation

Funding

This work was supported by the Guangzhou Municipal Science and Technology Program (No. 2023B03J0056), the Natural Science Foundation of Guangdong Province (Nos. 2024A1515012062 and 2021A1515010725), and the Scientific Research Project of Guangdong Provincial Bureau of Traditional Chinese Medicine (No. 20254028).

Declaration of competing interest

These authors have no conflict of interest to declare.

Supporting information

Supporting information for this work can be obtained by contacting the corresponding authors via E-mail.

References

[1] Song SS, Guo YY, Yang YH, et al. Advances in pathogenesis and therapeutic strategies for osteoporosis. Pharmacol Ther. 2022; 237:108168. https://doi.org/10.1016/j.pharmthera.2022.108168.

[2] Yao Y, Cai XY, Chen Y, et al. Estrogen deficiency-mediated osteoimmunity in postmenopausal osteoporosis. Med Res Rev. 2025; 45(2):561-575. https://doi.org/10.1002/med.22081.

[3] Tao HQ, Li WM, Zhang W, et al. Urolithin A suppresses RANKL-induced osteoclastogenesis and postmenopausal osteoporosis by, suppresses inflammation and downstream NF-κB activated pyroptosis pathways. Pharmacol Res. 2021; 174:105967. https://doi.org/10.1016/j.phrs.2021.105967.

[4] Patel D, Wairkar S. Bone regeneration in osteoporosis: opportunities and challenges. Drug Deliv Transl Res. 2023; 13(2):419-432. https://doi.org/10.1007/s13346-022-01222-6.

[5] Wang LT, Chen LR, Chen KH. Hormone-related and drug-induced osteoporosis: a cellular and molecular overview. Int J Mol Sci. 2023; 24(6):5814. https://doi.org/10.3390/ijms24065814.

[6] Ensrud KE, Crandall CJ. Osteoporosis. Ann Intern Med. 2017; 167(3):ITC17-ITC32. https://doi.org/10.7326/AITC201708010.

[7] Li J, Chen X, Lu LY, et al. The relationship between bone marrow adipose tissue and bone metabolism in postmenopausal osteoporosis. Cytokine Growth Factor Rev. 2020; 52:88-98. https://doi.org/10.1016/j.cytogfr.2020.02.003.

[8] Cui YZ, Lv B, Li ZY, et al. Bone-targeted biomimetic nanogels re-establish osteoblast/osteoclast balance to treat postmenopausal osteoporosis. Small. 2024; 20(6):e2303494. https://doi.org/10.1002/smll.202303494.

[9] Liu X, An JJ. Dietary iron intake and its impact on osteopenia/osteoporosis. BMC Endocr Disord. 2023; 23(1):154. https://doi.org/10.1186/s12902-023-01389-0.

[10] Huang YR, Zhang J, Zhu YF, et al. BMP9 alleviates iron accumulation-induced osteoporosis via the USP10/FOXO1/GPX4 axis. J Adv Res. 2026; 79:953-972. https://doi.org/10.1016/j.jare.2025.03.012.

[11] Cai H, Zhang HM, He WT, et al. Iron accumulation and its impact on osteoporotic fractures in postmenopausal women. J Zhejiang Univ Sci B. 2023; 24(4):301-311. https://doi.org/10.1631/jzus.B2200519.

[12] Ru Q, Li YS, Xie WQ, et al. Fighting age-related orthopedic diseases: focusing on ferroptosis. Bone Res. 2023; 11(1):12. https://doi.org/10.1038/s41413-023-00247-y.

[13] Zhang H, Wang AF, Li GF, et al. Osteoporotic bone loss from excess iron accumulation is driven by NOX4-triggered ferroptosis in osteoblasts. Free Radic Biol Med. 2023; 198:123-136. https://doi.org/10.1016/j.freeradbiomed.2023.01.026.

[14] Ma JW, Wang AF, Zhang H, et al. Iron overload induced osteocytes apoptosis and led to bone loss in Hepcidin^-/- mice through increasing sclerostin and RANKL/OPG. Bone. 2022; 164:116511. https://doi.org/10.1016/j.bone.2022.116511.

[15] Zhang C, Meng T, Dan Z, et al. Minocycline ameliorates osteoporosis induced by ovariectomy (OVX) and iron accumulation via iron chelation, bone metabolism regulation and inhibition of oxidative stress. QJM. 2020; 116(11):969. https://doi.org/10.1093/qjmed/hcaa271.

[16] Torti SV, Manz DH, Paul BT, et al. Iron and cancer. Annu Rev Nutr. 2018; 38:97-125. https://doi.org/10.1146/annurev-nutr-082117-051732.

[17] Guo Q, Qian C, Qian ZM. Iron metabolism and atherosclerosis. Trends Endocrinol Metab. 2023; 34(7):404-413. https://doi.org/10.1016/j.tem.2023.04.003.

[18] Jiang ZX, Qi GB, He XC, et al.Ferroptosis in osteocytes as a target for protection against postmenopausal osteoporosis. Adv Sci (Weinh). 2024; 11(12):e2307388. https://doi.org/10.1002/advs.202307388.

[19] Zhu LW, You YC, Zhu MX, et al. Ferritin-Hijacking nanoparticles spatiotemporally directing endogenous ferroptosis for synergistic anticancer therapy. Adv Mater. 2022; 34(51):e2207174. https://doi.org/10.1002/adma.202207174.

[20] Stockwell BR. Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications. Cell. 2022; 185(14):2401-2421. https://doi.org/10.1016/j.cell.2022.06.003.

[21] Yun J, Rocic P, Pung YF, et al. Redox-dependent mechanisms in coronary collateral growth: the “redox window” hypothesis. Antioxid Redox Signal. 2009; 11(8):1961-1974. https://doi.org/10.1089/ars.2009.2476.

[22] Cen WJ, Feng Y, Li SS, et al. Iron overload induces G₁ phase arrest and autophagy in murine preosteoblast cells. J Cell Physiol. 2018; 233(9):6779-6789. https://doi.org/10.1002/jcp.26405.

[23] Jing XZ, Du T, Chen K, et al. Icariin protects against iron overload-induced bone loss via suppressing oxidative stress. J Cell Physiol. 2019; 234(7):10123-10137. https://doi.org/10.1002/jcp.27678.

[24] Yang F, Yang L, Li Y, et al. Melatonin protects bone marrow mesenchymal stem cells against iron overload-induced aberrant differentiation and senescence. J Pineal Res. 2017; 63(3):12422. https://doi.org/10.1111/jpi.12422.

[25] Luo C, Xu WJ, Tang X, et al. Canonical Wnt signaling works downstream of iron overload to prevent ferroptosis from damaging osteoblast differentiation. Free Radic Biol Med. 2022; 188:337-350. https://doi.org/10.1016/j.freeradbiomed.2022.06.236.

[26] Kapoor R, Sirohi VK, Gupta K, et al. Naringenin ameliorates progression of endometriosis by modulating Nrf2/Keap1/HO1 axis and inducing apoptosis in rats. J Nutr Biochem. 2019; 70:215-226. https://doi.org/10.1016/j.jnutbio.2019.05.003.

[27] Zhang DD. Thirty years of NRF2: advances and therapeutic challenges. Nat Rev Drug Discov. 2025; 24(6):421-444. https://doi.org/10.1038/s41573-025-01145-0.

[28] Zheng DC, Liu ZM, Zhou Y, et al. Urolithin B, a gut microbiota metabolite, protects against myocardial ischemia/reperfusion injury via p62/Keap1/Nrf2 signaling pathway. Pharmacol Res. 2020; 153:104655. https://doi.org/10.1016/j.phrs.2020.104655.

[29] Li YC, Xu B, Ren XY, et al.Inhibition of CISD2 promotes ferroptosis through ferritinophagy-mediated ferritin turnover and regulation of p62-Keap1-NRF2 pathway. Cell Mol Biol Lett. 2022; 27(1):81. https://doi.org/10.1186/s11658-022-00383-z.

[30] Ong AJS, Bladen CE, Tigani TA, et al. The KEAP1-NRF2 pathway regulates TFEB/TFE3-dependent lysosomal biogenesis. Proc Natl Acad Sci U S A. 2023; 120(22):e2217425120. https://doi.org/10.1073/pnas.2217425120.

[31] Chen L, Ning JL, Linghu L, et al.USP13 facilitates a ferroptosis-to-autophagy switch by activation of the NFE2L2/NRF2-SQSTM1/p62-KEAP1 axis dependent on the KRAS signaling pathway. Autophagy. 2025; 21(3):565-582. https://doi.org/10.1080/15548627.2024.2410619.

[32] Park JY, Kim S, Sohn HY, et al. TFEB activates Nrf 2 by repressing its E3 ubiquitin ligase DCAF11 and promoting phosphorylation of p62. Sci Rep. 2019; 9(1):14354. https://doi.org/10.1038/s41598-019-50877-8.

[33] Butnariu M, Caunii A, Putnoky S. Reverse phase chromatographic behaviour of major components in Capsicum annuum extract. Chem Cent J. 2012; 6(1):146. https://doi.org/10.1186/1752-153x-6-146.

[34] Butnariu M. An analysis of Sorghum halepense’s behavior in presence of tropane alkaloids from Datura stramonium extracts. Chem Cent J. 2012; 6(1):75. https://doi.org/10.1186/1752-153x-6-75.

[35] Wang QY, Ou YJ, Hu GM, et al. Naringenin attenuates non-alcoholic fatty liver disease by down-regulating the NLRP3/NF-kappaB pathway in mice. Br J Pharmacol. 2020; 177(8):1806-1821. https://doi.org/10.1111/bph.14938.

[36] Butnariu M, Quispe C, Herrera-Bravo J, et al. The effects of thymoquinone on pancreatic cancer: evidence from preclinical studies. Biomed Pharmacother. 2022; 153:113364. https://doi.org/10.1016/j.biopha.2022.113364.

[37] Tutunchi H, Naeini F, Ostadrahimi A, et al. Naringenin, a flavanone with antiviral and anti-inflammatory effects: a promising treatment strategy against COVID-19. Phytother Res. 2020; 34(12):3137-3147. https://doi.org/10.1002/ptr.6781.

[38] Hua YQ, Zeng Y, Xu J, et al. Naringenin alleviates nonalcoholic steatohepatitis in middle-aged Apoe^(-/-) mice: role of SIRT1. Phytomedicine. 2021; 81:153412. https://doi.org/10.1016/j.phymed.2020.153412.

[39] Zaragoza C, Villaescusa L, Monserrat J, et al. Potential therapeutic anti-inflammatory and immunomodulatory effects of dihydroflavones, flavones, and flavonols. Molecules. 2020; 25(4):1017. https://doi.org/10.3390/molecules25041017.

[40] Motallebi M, Bhia M, Rajani HF, et al. Naringenin: a potential flavonoid phytochemical for cancer therapy. Life Sci. 2022; 305:120752. https://doi.org/10.1016/j.lfs.2022.120752.

[41] Cao SY, Wang Y, Zhang YL, et al. Naringenin can inhibit the pyroptosis of osteoblasts by activating the Nrf2/HO-1 signaling pathway and alleviate the differentiation disorder of osteoblasts caused by microgravity. J Agric Food Chem. 2024; 72(46):25586-25600. https://doi.org/10.1021/acs.jafc.4c05370.

[42] Jin H, Jiang NN, Xu WS, et al. Effect of flavonoids from Rhizoma Drynariae on osteoporosis rats and osteocytes. Biomed Pharmacother. 2022; 153:113379. https://doi.org/10.1016/j.biopha.2022.113379.

[43] Li PY, Zhang S, Song H, et al. Naringin promotes skeletal muscle fiber remodeling by the AdipoR1-APPL1-AMPK signaling pathway. J Agric Food Chem. 2021; 69(40):11890-11899. https://doi.org/10.1021/acs.jafc.1c04481.

[44] Zhang GD, Li XF, Wu L, et al. Piezo1 channel activation in response to mechanobiological acoustic radiation force in osteoblastic cells. Bone Res. 2021; 9(1):16. https://doi.org/10.1038/s41413-020-00124-y.

[45] Wu GJ, Chen KY, Yang JD, et al. Naringin improves osteoblast mineralization and bone healing and strength through regulating estrogen receptor alpha-dependent alkaline phosphatase gene expression. J Agric Food Chem. 2021; 69(44):13020-13033. https://doi.org/10.1021/acs.jafc.1c04353.

[46] Wang F, Weng ZB, Song HZ, et al. Ferric ammonium citrate (FAC)-induced inhibition of osteoblast proliferation/differentiation and its reversal by soybean-derived peptides (SDP). Food Chem Toxicol. 2021; 156:112527. https://doi.org/10.1016/j.fct.2021.112527.

[47] Che JM, Lv HH, Yang JC, et al. Iron overload induces apoptosis of osteoblast cells via eliciting ER stress-mediated mitochondrial dysfunction and p-eIF2alpha/ATF4/CHOP pathway in vitro. Cell Signal. 2021; 84:110024. https://doi.org/10.1016/j.cellsig.2021.110024.

[48] Huang CK, Gan DK, Luo FY, et al. Interaction mechanisms between the NOX4/ROS and RhoA/ROCK1 signaling pathways as new anti- fibrosis targets of ursolic acid in hepatic stellate cells. Front Pharmacol. 2019; 10:431. https://doi.org/10.3389/fphar.2019.00431.

[49] Bock FJ, Tait SWG. Mitochondria as multifaceted regulators of cell death. Nat Rev Mol Cell Biol. 2020; 21(2):85-100. https://doi.org/10.1038/s41580-019-0173-8.

[50] Drummen GP, van Liebergen LC, Op den Kamp JA, et al. C11-BODIPY(581/591), an oxidation-sensitive fluorescent lipid peroxidation probe: (micro)spectroscopic characterization and validation of methodology. Free Radic Biol Med. 2002; 33(4):473-490. https://doi.org/10.1016/s0891-5849(02)00848-1.

[51] Sinha K, Das J, Pal PB, et al. Oxidative stress: the mitochondria-dependent and mitochondria-independent pathways of apoptosis. Arch Toxicol. 2013; 87(7):1157-1180. https://doi.org/10.1007/s00204-013-1034-4.

[52] Xian YS, Liu B, Shen T, et al. Enhanced SIRT3 expression restores mitochondrial quality control mechanism to reverse osteogenic impairment in type 2 diabetes mellitus. Bone Res. 2025; 13(1):30. https://doi.org/10.1038/s41413-024-00399-5.

[53] Sun XJ, Xiao SJ, Ma WQ, et al. Activation of TFEB protects against diabetic vascular calcification by improving autophagic flux and activating Nrf 2 antioxidant system. Am J Physiol Endocrinol Metab. 2025; 328(6):E924-E939. https://doi.org/10.1152/ajpendo.00161.2023.

[54] Tan CT, Chang HC, Zhou QL, et al. MOAP-1-mediated dissociation of p62/SQSTM1 bodies releases Keap1 and suppresses Nrf 2 signaling. EMBO Rep. 2021; 22(1):e50854. https://doi.org/10.15252/embr.202050854.

[55] Polyzos SA, Anastasilakis AD, Efstathiadou ZA, et al. Postmenopausal osteoporosis coexisting with other metabolic diseases: treatment considerations. Maturitas. 2021; 147:19-25. https://doi.org/10.1016/j.maturitas.2021.02.007.

[56] Zhang XB, Liang YS, Zhang FY, et al. Osteoporosis: molecular pathogenesis and therapeutic interventions. Mol Biomed. 2025; 6(1):98. https://doi.org/10.1186/s43556-025-00349-5.

[57] Wang D, Shen JH, Wang Y, et al. Mechanisms of ferroptosis in bone disease: a new target for osteoporosis treatment. Cell Signal. 2025; 127:111598. https://doi.org/10.1016/j.cellsig.2025.111598.

[58] Zhang QL, Zhao L, Shen Y, et al. Curculigoside protects against excess-iron-induced bone loss by attenuating Akt-FoxO1-dependent oxidative damage to mice and osteoblastic MC3T3-E1 cells. Oxid Med Cell Longev. 2019; 2019:9281481. https://doi.org/10.1155/2019/9281481.

[59] Baschant U, Altamura S, Steele-Perkins P, et al. Iron effects versus metabolic alterations in hereditary hemochromatosis driven bone loss. Trends Endocrinol Metab. 2022; 33(9):652-663. https://doi.org/10.1016/j.tem.2022.06.004.

[60] Gera S, Sampathi S, Maddukuri S, et al. Therapeutic potential of naringenin nanosuspension: in vitro and in vivo anti-osteoporotic studies. Pharmaceutics. 2022; 14(7):1449. https://doi.org/10.3390/pharmaceutics14071449.

[61] Cui ZC, Gu GH, Chen F, et al. Targeting Irgm1 to combat osteoporosis: suppressing ROS and restoring bone remodeling. Cell Death Dis. 2025; 16(1):651. https://doi.org/10.1038/s41419-025-07965-7.

[62] Ford SA, King KC. In vivo microbial coevolution favors host protection and plastic downregulation of immunity. Mol Biol Evol. 2021; 38(4):1330-1338. https://doi.org/10.1093/molbev/msaa292.

[63] Yang L, Wang H, Yang X, et al. Auranofin mitigates systemic iron overload and induces ferroptosis via distinct mechanisms. Signal Transduct Target Ther. 2020; 5(1):138. https://doi.org/10.1038/s41392-020-00253-0.

[64] Tian Q, Qin B, Gu YF, et al. ROS-mediated necroptosis is involved in iron overload-induced osteoblastic cell death. Oxid Med Cell Longev. 2020; 2020:1295382. https://doi.org/10.1155/2020/1295382.

[65] Zhao HJ, Zhang JJ, Liu XC, et al. The antioxidant activities of alkalic-extractable polysaccharides from Coprinus comatus on alcohol-induced liver injury in mice. Sci Rep. 2018; 8(1):11695. https://doi.org/10.1038/s41598-018-30104-6.

[66] Huan H, Lyamzaev KG, Panteleeva AA, et al. Mitochondrial lipid peroxidation is necessary but not sufficient for induction of ferroptosis. Front Cell Dev Biol. 2024; 12:1452824. https://doi.org/10.3389/fcell.2024.1452824.

[67] Zeng WJ, Wang FX, Cui ZK, et al. Inhibition of ferroptosis counteracts the advanced maternal age-induced oocyte deterioration. Cell Death Differ. 2025; 32(6):1071-1085. https://doi.org/10.1038/s41418-025-01456-0.

[68] Huan XJ, Li JG, Chu ZB, et al. Dysregulation of iron homeostasis mediated by FTH increases ferroptosis sensitivity in TP53-mutant glioblastoma. Neurosci Bull. 2025; 41(4):569-582. https://doi.org/10.1007/s12264-024-01322-y.

[69] Nobuta H, Yang N, Ng YH, et al. Oligodendrocyte death in Pelizaeus-Merzbacher disease is rescued by iron chelation. Cell Stem Cell. 2019; 25(4):531-541.e6. https://doi.org/10.1016/j.stem.2019.09.003.

[70] Camiolo G, Barbato A, Giallongo C, et al. Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib. Redox Biol. 2020; 36:101611. https://doi.org/10.1016/j.redox.2020.101611.

[71] Xia F, Fu YY, Xie HZ, et al. Suppression of ATG4B by copper inhibits autophagy and involves in Mallory body formation. Redox Biol. 2022; 52:102284. https://doi.org/10.1016/j.redox.2022.102284.

[72] Hao L, Zhang AB, Lv DS, et al. EGCG activates Keap1/P62/Nrf2 pathway, inhibits iron deposition and apoptosis in rats with cerebral hemorrhage. Sci Rep. 2024; 14(1):31474. https://doi.org/10.1038/s41598-024-82938-y.

[73] Palma FR, Gantner BN, Sakiyama MJ, et al. ROS production by mitochondria: function or dysfunction?. Oncogene. 2024; 43(5):295-303. https://doi.org/10.1038/s41388-023-02907-z.

[74] DiGiovanni LF, Khroud PK, Carmichael RE, et al. ROS transfer at peroxisome-mitochondria contact regulates mitochondrial redox. Science. 2025; 389(6756):157-162. https://doi.org/10.1126/science.adn2804.

[75] Wu Y, Xun Y, Zhang JQ, et al. Resveratrol attenuates oxalate-induced renal oxidative injury and calcium oxalate crystal deposition by regulating TFEB-induced autophagy pathway. Front Cell Dev Biol. 2021; 9:638759. https://doi.org/10.3389/fcell.2021.638759.

[76] Zhang J, Zhang MZ, Tatar M, et al. Keap1-independent Nrf2 regulation: a novel therapeutic target for treating kidney disease. Redox Biol. 2025; 82:103593. https://doi.org/10.1016/j.redox.2025.103593.

[77] Sanchez-de-Diego C, Pedrazza L, Pimenta-Lopes C, et al. NRF2 function in osteocytes is required for bone homeostasis and drives osteocytic gene expression. Redox Biol. 2021; 40:101845. https://doi.org/10.1016/j.redox.2020.101845.

[78] Liberti D, Alfieri ML, Monti DM, et al. A melanin-related phenolic polymer with potent photoprotective and antioxidant activities for dermo-cosmetic applications. Antioxidants (Basel). 2020; 9(4):270. https://doi.org/10.3390/antiox9040270.

[79] Kong L, Deng J, Zhou X, et al. Sitagliptin activates the p62-Keap1-Nrf2 signalling pathway to alleviate oxidative stress and excessive autophagy in severe acute pancreatitis-related acute lung injury. Cell Death Dis. 2021; 12(10):928. https://doi.org/10.1038/s41419-021-04227-0.

[80] Wang XX, Li M, Xu XW, et al. BNIP3-mediated mitophagy attenuates hypoxic-ischemic brain damage in neonatal rats by inhibiting ferroptosis through P62-KEAP1-NRF2 pathway activation to maintain iron and redox homeostasis. Acta Pharmacol Sin. 2025; 46(1):33-51. https://doi.org/10.1038/s41401-024-01365-x.